Skip to main content
. 2020 Aug 13;7(19):2001447. doi: 10.1002/advs.202001447

Figure 2.

Figure 2

Sequencing for screening cancer immunotherapy. A) Schematic of combining sequencing and mass spectrometry to identify mutated peptides capable of being presented by MHC I. B) Tumor growth rate of mice immunized with either identified mutated peptide with adjuvants (Adj + Pep) or only adjuvant (Adj). Reproduced with permission.[ 70 ] Copyright 2014, Nature Publishing Group. C) Workflow of applying sequencing for cancer immunotherapy screening from six treatment‐naïve hepatocellular carcinoma (HCC) patients based on exome‐ and RNA‐sequencing for identification of subsets of T cells. Reproduced with permission.[ 71 ] Copyright 2017, Elsevier.